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1. Introduction
The Expected Value of Sample Information (EVSI) [ 1] uses evidence about the cost and
effectiveness of new treatments to determine the expected economic benefit of undertaking a
proposed study [ 2]. The EVSI calculates this value by determining the extent to which the
additional information from the study reduces the probability and expected loss of making
inefficient treatment recommendations [ 3]. In general, an inefficient recommendation would
spend health resources that would be used to improve patient outcomes elsewhere. Additionally,
information from future studies has the potential to improve patient outcomes within the disease
area under investigation.
As the EVSI calculates the value of a specific trial, it has the potential to be used to
determine the optimal allocation of research funding. Despite this, the EVSI has rarely been used
in practical scenarios [ 4]. This is partly due to the large computational effort required to calculate
the EVSI using the “gold-standard” nested Monte Carlo method [ 2].
Recently, a number of methods have been developed to reduce the computation time for
the EVSI [ 5, 6, 7, 8, 9, 10]. While computationally efficient, these methods require the use of
additional statistical techniques, e.g. specifying sufficient statistics [ 11], and may impose
restrictions on the underlying economic model. Therefore, EVSI calculations have been
repeatedly undertaken using Monte Carlo procedures, either using approximations to avoid
nested simulations [ 12, 13, 14], or with high computational cost [ 15, 16, 17, 18]
Using nested Monte Carlo methods is advantageous as it can be used irrespective of the
complexity of the economic model. Additionally, the EVSI is often understood in terms of this
nested Monte Carlo estimation procedure [ 19, 20, 5, 8] making the computation method easier to
comprehend. To utilise these advantages, Heath et al developed a computationally efficient EVSI
calculation method based solely on nested sampling [ 10] to calculate the EVSI in all practical
scenarios, within a reasonable timeframe.
The validity of this method has been demonstrated elsewhere [ 10] and thus this paper is
focused on presenting its practical implementation. Section 2 introduces the EVSI, key notation
and the nested Monte Carlo method. Section 3 outlines the efficient Monte Carlo method using a
simple “toy”. Finally, Section 4 investigates the optimal choice of the key input for this efficient
Monte Carlo method using an economic model evaluating a new Chemotherapy treatment [ 21].
2. Formal definition of the EVSI
In general, information has value as it reduces uncertainty in the inputs of a health
economic model, denoted ࣂ. Therefore, to calculate the EVSI, we must model the current level of
uncertainty in ࣂ using probability distributions that indicate the most plausible range for these
inputs. This is performed as part of a Probabilistic Sensitivity Analysis (PSA) [ 22, 23] where the
parameters of these distributions are usually informed by literature reviews alongside clinical
trials and expert opinion.
To value each of the treatment options, normally using a net benefit function [ 24], the
model inputs are combined using an economic model. To ease our explanation, we assume
throughout that this economic model only compares two treatment options – typically, an
innovative treatment and the standard of care. The output of the economic model is then the
incremental net benefit (INB), i.e. the difference between the net benefit of the innovative
treatment and net benefit of the standard of care. In this setting, uncertainty in the model inputs
implies that the INB is also uncertain. From this, we conclude that the innovative treatment is
optimal given current uncertainty if the average INB is greater than 0 and the standard of care is
optimal otherwise [ 22].
Figure 1 presents a pictorial description of the EVSI; the top panel shows the PSA process
where the value of the optimal treatment is some monetary value, say $ܥ. To calculate the EVSI,
we consider that additional information, denoted by ࢄ, is going to be collected in a future study,
e.g. a clinical trial or an observational study, to reduce the uncertainty in some of the model
inputs. If ࢄ had been collected, i.e. the future study had already been conducted, then the decision
making process would be exactly as we have already described. The information in ࢄ would be
formally included in the PSA distributions and the value of the optimal decision given this
additional information would be either 0, if the average INB is negative, or the average INB
itself, equal to $ܨ in the bottom of Figure 1. Comparing $ܨ with $ܥ gives the Value of the
Sample Information (VSI).
In general, we can consider the PSA distributions to be the prior for ࣂ, which is combined
with the data ࢄ using Bayes Theorem to compute the posterior distribution for ࣂ. This in turn
implies a posterior distribution for the INB.
However, as the future study has not been run (and potentially will never be), we define
a distribution over the possible, yet unknown study outcomes. The EVSI is then equal to the
average VSI over all these possible future datasets. Mathematically, it can be expressed in
terms of the INB as
EVSI = ܧࢄ mൣax൛0,ܧࣂ|ࢄ[ܰܫ ܤ]ൟ൧−max{0,ܧࣂ[ܰܫ ܤ]}
where ܧࣂ|ࢄ[ܰܫ ܤ] is the posterior expectation of the INB for a specific sample ࢄ. Typically, ࢄ
will only directly update a small number of model parameters, but in a Bayesian setting we still
take expectation with respect to the joint posterior distribution ݌(ࣂ|ࢄ).
To model the possible study outcomes, we specify the sampling distribution for the
data, had they been collected. This will depend on some of the model inputs: for example, a
binomial distribution models the number of people responding to a treatment conditional on the
success rate of the drug. Combining this sampling distribution, conditional on the model inputs,
with the PSA distributions for the model inputs gives a distribution over the potential future
datasets. This process is represented by the red arrow in Figure 1.
PSA is normally undertaken using a simulation approach [ 22, 21, 25] where ܵ
simulations are taken from the distribution of the model inputs. Each of these simulations is then
fed through the economic model to calculate ܵ simulations from the distribution of the INB,
denoted INB௦ for ݏ= 1, … , .ܵ
To calculate the EVSI, a potential future dataset denoted ࢄ௦ is then simulated for each
PSA simulation ݏ= 1, … , .ܵ This uses the sampling distribution for ࢄ conditional on a subset of
the model inputs. Each of these simulated datasets is used to find the posterior for the model
inputs and thus the posterior of the INB. In the most general setting, this updating uses Monte
Carlo methods, particularly Markov Chain Monte Carlo (MCMC) methods. This means ܴ
simulations are taken from the posterior distribution of the model inputs to calculate the average
INB.
Consequently, to calculate the EVSI by Monte Carlo requires ܵ× ܴ simulations, which
can be relatively computationally expensive for standard choices of ܵ (normally around 1000)
and ܴ (at least 600 [ 26]).
The method presented in this paper uses a nested Monte Carlo scheme but finds the
posterior distribution of the model inputs for a small number of potential future datasets.
Specifically, the required number of posterior updates reduces from ܵ to ܳ < 100. This
maintains the flexibility of the nested Monte Carlo method whilst drastically reducing its
computational cost, irrespective of the model structure.
3. The moment matching method
The efficient nested Monte Carlo method [ 10] is based on “moment matching” and
requires several elements. To begin, we must estimate the mean ߤࣂ and variance ߪࣂଶ of the INB,
using the PSA simulations.
3.1. Uncertainty due to key parameters
As previously discussed, the sampling distribution of ࢄ, typically, only depends directly
on a small number of the model inputs. For example, within a full health economic model, a
clinical trial would focus on the epidemiological parameters and not the economic disease
burden. To formalise this, we assume that the model inputs split into two categories, (ࣘ ,࣒),
where the sampling distribution for ࢄ is based solely on the inputs ࣘ (e.g. the epidemiological
parameters) and all the remaining inputs are in ࣒ . The moment matching method requires the
distribution of the INB where uncertainty due to the model inputs in ࣒ has been marginalised
out. This is expressed mathematically as
INBࣘ = ܧ࣒ |ࣘ [INB(ࣘ ,࣒)].
Notice that this quantity is required to calculate an alternative Value of Information
measure known as the Expected Value of Partial Perfect Information (EVPPI) [ 6], which
quantifies the economic value of learning the exact value of the model inputs ࣘ . As study
information cannot give exact information, the EVPPI for ࣘ is an upper bound for the EVSI. If
this upper bound is low then there is no value in a study targeting ࣘ and so the modeller can
discount a trial targeting ࣘ before determining a sampling distribution for ࢄ. Therefore, the
EVPPI should always be calculated before proceeding to the EVSI [ 27], which means that the
INBࣘ values should already be available. Several methods have been developed to estimate the
EVPPI [ 28, 29, 30] and, more importantly, general purpose software is available to calculate
INBࣘ directly from the PSA simulations [ 31, 32, 33].
3.2. The nested posterior variance
The final element required to estimate the EVSI is the variance of the posterior INB,
across different possible future samples. Specifically, the variance of the posterior INB is
inversely proportional to the EVSI. This is because the decision between the two treatment
options becomes more certain as the posterior variance of the INB decreases.
To estimate the expected variance of the posterior INB, we use a nested Monte Carlo
method. This is the same process as the “gold standard” EVSI estimation method where potential
datasets are simulated conditional on values for ࣘ and used to find posteriors for the model
inputs using MCMC. The economic model is then used to calculate posterior distributions of the
INB using simulations for the model inputs. The only difference between the two methods is that
the moment matching method requires an estimate of the variance of the posterior INB, rather
than its mean.
To accurately estimate the EVSI, the variance of the posterior INB must be estimated for
a number of potential datasets, say ܳ. Theoretically, ܳ should be greater than 30, as accurate
estimation of the variance depends on the central limit theorem, but, the variance of the posterior
INB is sufficiently accurate for values of ܳ close to 30 [ 10], provided the future datasets are
simulated using the following procedure.
Loosely, we want to “space-out” the simulated future datasets to accurately estimate the
EVSI. To achieve this, we find ܳ equally spaced values of ࣘby determining the quantiles of the
PSA simulations and use these to generate the future datasets. Practically, we proceed by
ordering the PSA simulations for each of the model inputs in ࣘ and selecting the ௤
ொାଵ
th elements
in these ordered lists for ݍ= 1, … ,ܳ . For example, if ܳ= 3 and the number of PSA
simulations ܵ= 1000, then each column in ࣘ should be ordered and the 250th, 500th and 750th
elements from each of these lists should be selected.
For each selected row in the ordered ࣘ list, we simulate one potential future sample from
the sampling distribution of ࢄ. These potential future samples are each used to find a posterior
distribution for the model inputs using MCMC. A posterior distribution for the INB is calculated
for each of the samples and the variance, denoted ߪ௤ଶ for ݍ= 1, … ,ܳ, is calculated.
3.3. Calculating the EVSI
To calculate the EVSI, we must combine all these different elements:
1. The mean of the INB from the PSA simulations ߤࣂ;
2. The variance of the INB from the PSA simulations ߪࣂଶ;
3. The INBࣘ values used to calculate the EVPPI;
4. The variance of the INBࣘ values, denoted ߪࣘଶ
5. The posterior variance of the INB calculated ܳ times using nested sampling ߪ௤ଶ for
ݍ= 1, … ,ܳ,
Firstly, we calculate the average posterior variance across the ܳ nested samples:
ߪࢄ
ଶ = 1ܳ ෍ ߪ௤ଶொ
௤ୀଵ
.
Finally, all the above elements are used to rescale the INBࣘ values:
INB∗ =
⎝
⎛
INBࣘ − ߤࣂ
ටߪࣘ
ଶ
⎠
⎞ටߪࣂ
ଶ−ߪࢄ
ଶ +ߤࣂ.
This gives ܵ rescaled INBࣘ values, where ܵ is the number of PSA simulations, which are then
used to estimate the EVSI,
EVSI෣ = 1ܵ෍ max{0, INB௦∗}ௌ
௦ୀଵ
−max{0,ߤࣂ}
3.4. Toy Example
To clarify the moment matching method, we estimate the EVSI in a very simple setting.
The effectiveness measure in this example is the probability of curing a disease. Information from
a previous trial implies that the uncertainty in this effectiveness measure for two treatments under
consideration can be modelled using the following Beta distributions ߨଵ~ܤ ݁ܽݐ (3,4) and
ߨଶ~ܤ ݁ܽݐ (4,3). A literature review determines that uncertainty in the incremental cost can be
modelled using a Normal distribution ߜ~ܰ݋݉ݎ ܽ (݈3,20). Therefore, in this example, ࣂ =(ߨଵ,ߨଶ,ߜ). We then define the INB for this model as
INB = 100(ߨଵ− ߨଶ) − ߜ(1)
where 100 is the selected willingness to pay. Note that this threshold is used for illustrative
purposes as the effectiveness measure is probability of a cure rather than Quality Adjusted Life
Years (QALYs).
For this model, we report PSA simulations for ܵ= 10 in Table 1. Each parameter is
simulated from its distribution and then each simulated row is used to calculate the INB using
equation (1). The mean and variance of the INB are calculated as ߤࣂ = −4.5 and ߪࣂଶ = 722.
Using an EVPPI analysis, we found that reducing uncertainty inߨଵ, the probability of a
cure for treatment 1, has the highest value. Therefore, we design a trial where treatment 1 is given
to 20 people and observe how many patients respond. This implies a Binomial sampling
distribution for the future study: ࢄ~ܤ݅݊ ݋݉ ݅ܽ (݈20,ߨଵ).
To calculate the EVSI, we determine the INB conditional on ߶ = ߨଵ. In this example, we
have used the EVPPI calculation method developed by Strong et al. 29 to calculate INBథ and the
values are given in Table 1. The variance of INBథ is then calculated, ߪథଶ = 391.
The final element required for the moment matching method is the posterior
variance estimated using nested sampling. For illustrative purposes, we set ܳ= 3. To
begin, we order the observed ߨଵ values, which produces the following vector:(0.26, 0.27, 0.30, 0.37, 0.47, 0.50, 0.51, 0.53, 0.59, 0.76).
We then select the 2.5th, 5.5th and 7.5th elements in this ordered list. Each of these values is
used to simulate a potential future sample from the sampling distribution ofܺ . Each future
sample generates a posterior for ߨଵ which then determines the posterior INB. In this
example, 100 simulations from the posterior of ߨଵ are combined with 100 simulations of ߨଶ
and ߜ to calculate the posterior INB and its variance. Table 2 demonstrates this process
giving the variance of the posterior INB for each sample and the average posterior variance
ߪࢄ
ଶ as 406.
We can now combine all the elements to rescale the INBథ values,
INB∗ =ቆINBࣘ − (−4.5)
√391 ቇ√722 − 406 + (−4.5).
These values are given in Table 1. Finally, the EVSI is estimated using moment matching,
as
EVSI = 110 (4 + 10 + 29 + 2) −max{0,−4.5} = 4.6
This example is illustrative of the moment matching method; in practice a large PSA
simulation size should be used, ideally in excess of 1000.
4. Calculating the EVSI: a new chemotherapy drug
To demonstrate the moment matching method and investigate the optimal value for ܳ, we
extend a model developed to compare a new chemotherapy treatment against the standard of care
[ 21]. In this model, the two treatments differ only in the number of side effects experienced, with
the new drug aiming to reduce it. This in turn reduces the cost of treating side effects, as they
require additional treatment, and increases the patient’s quality of life.
There are 14 model inputs related to the cost and QALYs associated with experiencing
side effects as well as the probability of experiencing side effects on either treatment. The
progression of the side effects is modelled using a four state Markov Model with further details
provided in the supplementary material, along with model code.
4.1. A trial investigating side effects of Chemotherapy treatment
To gather more information for this model, we designed a trial where both treatments
would be given to 150 patients. In the main, this trial will inform the probability of side effects
for each treatment. As a secondary outcome, we also study the disease progression of any of the
patients experiencing side effects. This directly informs the transition probabilities of the Markov
Model for side effects treatment. An EVPPI analysis demonstrated that gaining perfect
information about these parameters would explain 90% of the model uncertainty. For simplicity,
we assumed complete compliance with the treatment and full follow-up. A full description of the
sampling distributions used for the EVSI analysis is given in the supplementary material.
4.2. The optimal number of nested samples
To find the optimal number of nested samples, we fix the total number of simulations
used to estimate the EVSI. Clearly, as with all simulation based methods, we increase the
accuracy of the EVSI estimate by increasing the total number of simulations. However, in fixing
the total computational cost we determine the relative importance of increasing ܳ versus
increasing the number of simulations from the posterior distribution of the model inputs.
We use two sizes of nested simulation, 500 000, with a computation time of between 108
and 129 seconds for one EVSI estimate and 5 000, with a computation time of between 9 and 17
seconds. We then considered 8 different values of ܳ = 20, 30, … , 100, where 20 is below the
recommended lower limit for ܳ [10]. As the EVSI is estimated by simulation, it is subject to
random variance. Therefore, we calculated the EVSI 200 times for each combination of ܳ and
simulation size. This allows us to calculate the variance of the EVSI estimate for each
combination (Figure 2) and the bias (Figure 3). To calculate the bias, we estimated the EVSI
using nested simulation with ܵ= 100 000 and ܴ = 100 000 with a computational cost of
around 60 days.
Figure 2 demonstrates that larger ܳ values produce more precise EVSI estimates as the
variance is smaller. This is true for both 500 000 and 5 000 simulations although the variance
seems to plateau earlier for 5 000 implying that increasing ܳ is less important when the number
of posterior simulations is not sufficient to estimate the posterior of ࣂ. Therefore, computational
effort should be used to increase ܳ and not ܴ, the number of simulations for each posterior.
Clearly, the variance of the estimated EVSI is lower with a greater number of simulation.
Figure 3 demonstrates that larger ܳ values produce more accurate EVSI estimates.
Nevertheless, the moment matching method seems to have a slight upward bias, reducing as ܳ
increases. Notice, that the bias is large for ܳ = 20, confirming that the moment matching method
should only be used with ܳ > 30.
In light of this analysis, ܳ should be chosen in the following manner. Firstly, determine
the number of simulations ܴ required to characterise the posterior distribution of ࣂ and the total
number of simulations available to estimate the EVSI. Then, ܳ should be equal to the total
number of simulations divided by ܴ. For example, if 50 000 posterior simulations can be used to
estimate the EVSI and ܴ = 1 000, then ܳ = 50 nested simulations should be used.
As a final comment, note that the INB∗ values are calculated using the difference between
the PSA variance of the INB ߪࣂଶ and the mean posterior variance ߪࢄଶ, from Equation (2).
Therefore, accurately estimating ߪࢄଶ using nested simulations is useless if ߪࣂଶ is poorly estimated.
Thus, the PSA simulations size ܵmust be relatively large. Additionally, the required accuracy of
the estimates of ߪࢄଶ and ߪࣂଶ actually depends on the size of the EVSI. For a small EVSI, the
posterior variance is close to the prior variance meaning that of ߪࢄଶ−ߪࣂଶ is small. As both
variances are estimated by simulation, the sampling variation could be larger than the “true"
difference, leading to inaccurate EVSI estimates. Therefore, the moment matching method should
only be used for studies where the EVPPI for ࣘ is high.
5. Conclusion
In this paper, we have presented an efficient Monte Carlo estimation method for the
EVSI. This method significantly reduces the number of nested simulations required to accurately
estimate the EVSI. This maintains the flexibility and comprehensibility of the nested Monte
Carlo method whist reducing computational time. The moment matching method was presented
in theoretical terms alongside an illustrative worked example. Finally, we explored the optimal
number of nested samples required to accurately estimate the EVSI. In general, the number of
nested samples should be taken as large as possible, whilst maintaining a feasible computational
cost and ensuring that the posterior distribution for the model inputs is adequately captured.
Another advantage of this efficient Monte Carlo method is that general purpose software
has been developed to perform these EVSI calculations [ 34]. Early results also indicate that this
method can be extended to estimate EVSI across different sample sizes with no additional
computational cost meaning that the EVSI could be used as a tool for trial design within a
realistic time frame.
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